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Abstract
Clinical trials investigating therapies for acutely and critically ill and injured patients in the earliest
phases of treatment often can only be performed under regulations allowing for exception from
informed consent (EFIC) for emergency research. Implementation of these regulations in multicenter
clinical trials involves special challenges and opportunities. The Rapid Anticonvulsant Medication Prior
to Arrival Trial (RAMPART), the first EFIC trial conducted by the Neurological Emergencies Treatment
Trials (NETT) network, combined centralized resources and coordination with retention of local control
and flexibility to facilitate compliance with the EFIC regulations. Specific methods used by the NETT
included common tools for community consultation and public disclosure, sharing of experiences and
knowledge, and reporting of aggregate results. Tracking of community consultation and public disclo-
sure activities and feedback facilitates empirical research on EFIC methods in the network and supports
quality improvements for future NETT trials. The NETT model used in RAMPART demonstrates how
EFIC may be effectively performed in established clinical trial networks.
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T he Neurological Emergencies Treatment Trials(NETT) network was created in 2007 by theNational Institute of Neurological Disorders and Stroke (NINDS) to perform clinical trials of interventionsgiven in the earliest phases of care for patients with acuteneurological illness and injury, such as stroke or neuro-
trauma.1 Because patients with these conditions are
often unresponsive, and the treatments being studied are
taking place in the ambulance or immediately on arrival
in the emergency department (ED), many trials in the
NETT can only be performed using a special set of fed-
eral regulations that govern emergency research. These
regulations allow for an exception from informed con-
sent (EFIC) for certain emergency circumstances and are
described in the Code of Federal Regulations at 21 CFR
50.24.2 In addition to specifying which types of studies
are eligible for EFIC, these regulations require
substantial pretrial community consultation and public
disclosure (CC ⁄PD) activities.2,3
Although many EFIC studies have been performed,
the processes of CC ⁄PD remain poorly described and
poorly understood. While sometimes used in other con-
texts, CC ⁄PD are not required by regulation for any
other type of research. In particular, little guidance
exists with regard to implementing EFIC processes
within large multicenter trials. Multicenter trials are
more complicated than single institution trials because
ISSN 1069-6563 ª 2012 by the Society for Academic Emergency Medicine
448 PII ISSN 1069-6563583 doi: 10.1111/j.1553-2712.2012.01328.x
From the Department of Emergency Medicine, University of
Michigan (RS, DH), Ann Arbor, MI; the Department of Emer-
gency Medicine, University of Minnesota (MHB), Minneapolis,
MN; the Division of Cardiology, Emory University (ND),
Atlanta, GA; and the Department of Emergency Medicine, Uni-
versity of Pennsylvania (JB), Philadelphia, PA.
*See appendix for a list of the NETT Investigators.
Received May 19, 2011; revision received October 14, 2011;
accepted October 16, 2011.
This work was primarily supported by award 5U01NS056975-04
from the National Institute of Neurological Disorders and Stroke
(NINDS), the Office of the Director, National Institutes of Health
(OD), BARDA, and the NIH CounterACT program.
The trial described in this work is registered with ClinicalTrials.
gov (NCT00809146).
The authors have no relevant financial information or potential
conflicts of interest to disclose.
Supervising Editor: Sandy Bogucki, MD, PhD.
Address for correspondence and reprints: Robert Silbergleit,
MD; e-mail: robert.silbergleit@umich.edu.
CC ⁄PD is conducted in more locations, interpretations
of many diverse institutional review boards (IRBs) must
be addressed, and results must be tracked and aggre-
gated across centers for reporting to oversight bodies
(IRBs, Food and Drug Administration [FDA], etc.).3–6
The presumption that processes should be customized
to meet the needs of local communities, coupled with a
lack of consensus about optimal CC ⁄PD practices, or
even the goals of such efforts, makes it difficult to stan-
dardize EFIC activities across a network. It is unknown
whether central coordination within a network helps to
address these issues.
The first NETT trial performed using EFIC is the
Rapid Anticonvulsant Medication Prior to Arrival Trial
(RAMPART). RAMPART compares intravenous (IV) ver-
sus intramuscular (IM) benzodiazepine anticonvulsants
for the prehospital treatment of status epilepticus in
adult and pediatric patients. Because establishing IV
access can be challenging in convulsing patients in the
field, IM midazolam has become increasingly popular
for emergency medical services (EMS) use, but its
safety and efficacy in this context have not been dem-
onstrated in a clinical trial. RAMPART is a randomized
double-blind, double-dummy multicenter noninferiority
clinical trial designed to provide this information (clini-
caltrials.gov identifier NCT00809146). The trial is being
conducted at all 17 NETT ‘‘hub’’ hospitals, each of
which is an academic medical center that coordinates
research activities at a number of ‘‘spoke’’ hospitals
and EMS systems.
We describe here the EFIC activities that took place
within the NETT in preparation for the RAMPART trial,
with emphasis on the special role an established net-
work infrastructure can play in improving such efforts.
The strategy was intended to optimize the protection of
human subjects, enhance regulatory compliance, sup-
port local autonomy, and improve efficiency. This strat-
egy, which employed novel methods of oversight and
collaboration, may serve as a model for other EFIC
trials conducted within large multicenter networks.
RAMPART TRIAL
Resources and Planning
At the outset, RAMPART investigators, as well as rele-
vant regulatory bodies, recognized that the RAMPART
trial would necessitate the use of EFIC. An EFIC plan
was thus developed centrally and was included in the
trial protocol,7 (also see Data Supplement S1, available
as supporting information in the online version of this
paper) and in an investigational new drug (IND)
application to the FDA.
Concurrent with the development of RAMPART EFIC
activities, a human subjects protections working group
was formed to coordinate and optimize NETT EFIC
activities. Members of the working group were drawn
from the NETT steering committee and study coordina-
tor group and from NETT sites based on interest and
expertise. The purpose was to coordinate and foster
empirical research related to EFIC.
RAMPART EFIC Meeting. Because participating
sites had varying levels of experience conducting EFIC
trials, the RAMPART trial leadership convened a pretri-
al meeting to provide education on the regulatory
aspects of 21 CFR 50.24. Investigators and study coor-
dinators from each site were invited to attend. IRB
members from NETT sites were also invited.
The meeting agenda included presentations from
investigators experienced in emergency research with
EFIC, ethicists, federal regulatory personnel, and IRB
directors. The full agenda of the meeting is included in
Data Supplement S1. Over the course of the 2-day
meeting, there was extensive discussion about EFIC
and opportunities for interaction between novice inves-
tigators and those with prior experience. The meeting
also served as a forum to create a strategy for address-
ing potential barriers identified during implementation
of the proposed trial. An opportunity was also available
for site investigators to record custom video introduc-
tion footage for use in later community consultation
activities. Finally, the meeting proceedings were used
to inform the next steps in implementation of EFIC
within RAMPART and the NETT.
Network Central Resources. EFIC implementation
was coordinated centrally by the NETT Clinical Coordi-
nating Center, and a full-time human subjects protec-
tion coordinator (HSPC) was hired for this task.
Initially, the Clinical Coordinating Center developed
generic templates for CC ⁄PD activities that could be
customized by sites for local implementation. This
material was based on existing information from expe-
rienced investigators and from advice given by federal
regulators.5,8 Educational videos, advertising templates,
sample IRB applications, and documents were also
developed by the Clinical Coordinating Center and
were placed in a Web-based repository alongside mate-
rials developed by individual sites to promote sharing
and reduce duplication of work.
The template EFIC plan included an overview of the
EFIC regulations, the rationale for conducting RAM-
PART under 21 CFR 50.24, how the investigators
planned to fulfill the requirements of the regulations,
and how the results would be summarized and submit-
ted to the IRB for its consideration. The EFIC plan also
included a menu of options for CC ⁄PD activities as sug-
gested by the FDA draft guidance document and prior
use in EFIC trials. Activities were categorized by
method of communication and the potential targeted
audience, and the pros and cons of each were
described. The intention was for sites to choose activi-
ties that were most likely to be locally feasible within a
reasonable time frame and which would yield the best
information for IRBs to use in their deliberations. Sites
were advised to consider the characteristics of their
local populations and community resources and to
choose a variety of complementary activities. Each site
was expected to submit a local EFIC plan to the Clinical
Coordinating Center for review and comments. Clinical
Coordinating Center staff worked with sites to refine
their plans and allowed for variability in EFIC plans as
deemed appropriate by local sites.
In addition to serving as a central contact and facili-
tator for EFIC within the network, the HSPC was able
to leverage the collective experience of the entire
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network to address individual site issues as they arose.
To provide oversight and assistance to sites, the HSPC
traveled to each site and directly observed community
consultation activities. She also participated in site
readiness telephone calls to assure that community con-
sultation was completed and that there was recent pub-
lic disclosure activity in relation to trial start date.
These activities allowed the HSPC to identify problems
and variances as they arose and seek rapid solutions or
intervention before significant regulatory or safety
issues developed.
Metrics of EFIC Progress. The progress of the EFIC
approval was tracked with a set of predetermined mile-
stones that were attached to a payment schedule (Data
Supplement S1, figure). Completion of milestones was
documented in a tracking database. This system
allowed for identification of sites having difficulty with
EFIC processes and allowed the HSPC to interact with
those sites to identify potential solutions.
Local investigators were encouraged to meet in
advance of protocol submission with their IRB to dis-
cuss their proposed EFIC plan and to seek further input
for CC ⁄PD activities. Once finalized, the EFIC plan was
submitted for formal IRB approval. After IRB approval
of the EFIC plan was obtained, sites performed CC ⁄PD
activities. Throughout the CC ⁄PD process, the HSPC
provided regular updates and shared information on
novel or unique approaches or findings with the steering
committee.
Community Consultation and Public Disclosure. The
human subjects protection working group recom-
mended the creation of a database to track EFIC
CC ⁄PD activities. The database consisted of electronic
data summary reporting forms that allowed for stan-
dardizing, aggregating, and sharing information col-
lected during CC ⁄PD activities. Summary data were
entered in the network’s centralized clinical trial man-
agement and data system. Sites provided estimates of
the population reached through public disclosure activi-
ties that were based on the reported audience reach of
media outlets. The database was accessible by any
interested investigator for regulatory or academic pur-
poses. A member of the human subjects protection
working group was appointed to serve as a member of
the trial’s operations committee.
Experience and Outcomes
Timeline. Funding for the NETT Clinical Coordinat-
ing Center, including resources to conduct RAMPART
as an EFIC trial and to conduct other trials, was
awarded from the NINDS and the Office of the Direc-
tor. The IND application was submitted to the FDA in
April 2008 and approved in October 2008. The FDA
raised no concerns about the use of 21 CFR 50.24 in
RAMPART or the proposed EFIC plans. Among the 17
hub sites, local EFIC plans were submitted to IRBs in
the first half of 2008 at seven hubs, in the second half of
2008 at seven hubs, and in 2009 at three hubs. An
investigator training meeting was held in January 2009;
enrollment in the study began in June 2009.
RAMPART EFIC Meeting. The RAMPART EFIC
meeting held in January 2008 was attended by 21 IRB
representatives (at least one from each hub); five invited
external presenters experienced in regulatory and
ethical aspects of emergency research; and 74 other
investigators, coordinators, and NIH representatives.
Video. Three videos were developed as central
resources. These 1) described the RAMPART study,
2) described the nature of clinical emergency medicine
research, and 3) addressed a series of likely questions
and answers. Investigators attending the RAMPART
EFIC meeting were given the opportunity to record
custom video introductions, and investigators from all
17 sites did so. The videos were created for a general
public audience. They were posted to the national trial
website and several hub-specific websites (links avail-
able in Data Supplement S1). Sites also used the videos
to create public service announcements for television;
as a multimedia aid in community consultation events;
and in social networking environments, including Face-
book and YouTube. Ten of the 17 sites ultimately used
the video for online streaming, with live presentations,
or for broadcast purposes. Complete Internet tracking
reports for online viewing of the videos are not avail-
able, but the combined number of viewings for RAM-
PART videos on YouTube is currently 946 (through
September 12, 2010). The videos were provided in short
segments that could be combined or reordered and
were otherwise customized to the needs of each site or
use. The cost to create the videos, using a professional
academic producer (Michigan Productions, Ann Arbor,
MI), was $22,000.
Toolbox. The Web-based toolbox containing both
materials developed centrally and shared materials
developed at hub sites included 153 unique documents
including templates for community consultation presen-
tations and public disclosure materials (slide sets, bro-
chures, advertisements, and surveys in English and
other languages). EFIC plans, IRB applications,
informed consent documents, and related resources for
training and enrollment were also uploaded to this
shared site.
Examples of the most commonly used centrally pro-
vided resources include the detailed EFIC plan tem-
plate, based on the plan submitted with the FDA, that
explained how the trial met criteria for use of EFIC and
provided a menu describing CC ⁄PD options along with
the rationale, advantages, and disadvantages of each
approach. Although sites customized their own EFIC
plans to address local IRB expectations, all sites used
the text from the provided EFIC plan template as their
starting point and chose approaches from the menu.
All sites also cut and pasted language from centrally
prepared templates for IRB applications and consent
forms, including descriptions of the protocol, descrip-
tions of risk and benefit, background, and other com-
mon components. The centrally provided slides and
brochures were also commonly used by study sites.
Examples of successful centrally facilitated site-to-site
sharing of EFIC community consultation resources
included a common script and survey shared by sites
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doing random-digit dialing, frequent exchanges of
slides and advertising copy between sites, and frequent
sharing of community consultation meeting survey
questions and focus group instruments.
Metrics of EFIC Progress. Hub sites were provided
monetary resources necessary to engage in a robust
EFIC process. Three payments were contingent on
achieving explicit prespecified milestones: 1) submission
of a local EFIC plan to the participating site IRB, 2) com-
pletion of a schedule of CC ⁄PD activities, and 3) local
IRB approval to begin enrollment. The interval between
the RAMPART EFIC meeting and the first EFIC mile-
stone ranged from 1 to 19 months with median of
5 months (interquartile range [IQR] = 2 to 8 months)
and a mean (±SD) of 7 (±6) months. The interval
required for community consultation from approval of
local EFIC plans to final IRB approval to start enroll-
ment ranged from 2 to 14 months, with a median of
7 months (IQR = 5 to 9 months) and a mean (±SD) of
7 (±3) months.
The trial protocol was reviewed and approved by 43
unique IRBs (many institutions and all EMS systems
deferred to other local IRBs). One municipal IRB
reviewed but did not approve an application to conduct
RAMPART in its city EMS system, citing liability and
other concerns. As required by 21 CFR 50.24(e), this
nonapproval was reported to other reviewing IRBs and
the FDA.
Community Consultations. For RAMPART, 225
NETT community consultation activities at 17 hubs
have been reported, involving over 23,898 participants.
Feedback from 6,846 individuals included 50,275
closed-ended responses and 2,635 open-ended
responses and comments. Qualitative coding of
responses expressing support or concern for EFIC
identified 79% of closed-ended answers and 77% of
open-ended comments as supportive. Table 1 describes
the frequency of various types of community consulta-
tion events and the number of reported participants
by type. The most common types of community con-
sultation activities included visits to existing group
meetings (43%) and focus groups or interviews (19%).
Other types of activities included a booth or table at
events (8%), town hall meetings (9%), phone surveys
(using random digit dialing) or Internet surveys (4%),
and call-in radio talk shows (1%). Unscheduled feed-
back (phone calls, e-mail, etc.) was also collected.
Table 2 shows how these activities and participation
were distributed by hub. Events were directed toward
geographical communities 68% of the time and seizure
risk–related communities in 32%. Groups involved
included the general public (56%), parents (13%), chil-
dren (8%), medical professionals (19%), ethnic or racial
groups (6%), religious groups (2%), civic leaders (8%),
and others (these add up to more than 100% because
some events involved multiple categories of partici-
pants). Participants in community consultation activi-
ties self-assessed their comprehension of key elements
of EFIC as being quite strong (detail provided in the
Data Supplement S1).
There was no important or statistically significant
interaction between the numbers of reported partici-
pants in community consultation activities by hub, the
number of events, the timing of IRB approval, or the
number of subjects eventually recruited at that hub hos-
pital. For submission to oversight bodies, aggregate
reports of community consultation results were pre-
pared using an automated standardized template that
both includes a ‘‘high-altitude’’ overview of summarized
findings and then includes detailed listings of individual
responses. The report, including both numerical and
graphical presentations of the community consultation
results from throughout the network, is included in
Data Supplement S1. A more detailed exploration of
the community consultation experience in RAMPART is
beyond the scope of this report and will be reported
separately.
Public Disclosure. There were 289 public disclosure
activities over 22 months reported at 17 hubs, with a
cumulative estimated potential target audience of
12,978,315 people. Pretrial activities took place between
April 26, 2008, and February 17, 2010, and the median
disclosure date was April 10, 2009 (IQR = November 21,
2008, to September 1, 2009). Further ongoing and post-
trial public disclosure activities are not reported here.
Traditional media were commonly used, including
newspaper stories or announcements in 18% and radio
and television broadcasts in 10%. These accounted for
75% of the estimated target audience. Electronic media
including e-mail distributions, on-line postings, and
website visits constituted another 19% of activities, and
contributed 11% of the estimated target audience.
Other methods of public disclosure included brochures,
posters, fliers, direct mailings, billboards, information
booths, presentations, and other communications. Dis-
closure activities were sometimes directed toward the
epilepsy community through stories or announcements
in epilepsy support or advocacy newsletters or through
the use of advertisements on public transportation,
since those with frequent seizures are less likely to
drive.
The estimated total cost to hubs for public disclo-
sure activities (excluding study team time or man-
power hours) was $105,711, although this underestimates
Table 1
Frequency and Number of Participants in RAMPART Community
Consultation Activities by Event Type
Type of Community
Consultation Event n (%) Participants
Existing group meeting 97 (43) 4,405
Focus group ⁄ face-to-face
interview
43 (19) 604
Unscheduled feedback 35 (16) 59
Town hall style meeting 21 (9) 256
Booth ⁄ table ⁄ exhibit 19 (8) 16,850




Other (call-in radio show) 2 (1) 17
RAMPART = Rapid Anticonvulsant Medication Prior to Arrival
Trial.
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the true dollar value of these activities since many sites
were able to leverage publicly funded or donated media
access. Public disclosure activities were reported to be
associated with a total of 14 requests to opt out of the
trial. If one interprets the purpose of public disclosure
as a means to allow potential subjects to opt out, this is
a remarkably low total that could reflect a low level of
concern about the trial or low penetration of the mes-
sage. If, however, the purpose of public disclosure is
primarily to ensure transparency in and of itself, then
the low number of opt-outs is a less important finding
because transparency per se does not require high
message penetration.
EMS Participation and EFIC. Thirty EMS services
operating in 14 states participated in the trial. The
majority of hubs worked with a single EMS agency, but
others involved as many as six. Two thirds of the sys-
tems were fire-service based, and the rest were private,
third-service, or hospital-based services. Participating
systems ranged widely in size, with 27% performing
<5,000 runs ⁄year and 20% performing >100,000 runs ⁄
year. EMS participation in EFIC community consulta-
tion activities was variable, but was infrequent at the
majority of sites. In several systems, however, para-
medics or EMS system leadership participated with the
investigators and other study team members in visits to
existing meetings or in presentations at town hall meet-
ings. No quantitative data on the frequency of this par-
ticipation were collected. One site obtained additional
NIH funding (5RC1NR011536-02) for a robust and suc-
cessful multifaceted approach to community consulta-
tion and engagement that included use of EMS
personnel as community liaisons.9,10
On another level, administrative approval of the trial
including EFIC was obtained from all participating
agencies. All EMS entities had or obtained a Federal
Wide Assurance (FWA) designating an IRB of record
or were explicitly covered under the FWA of the insti-
tution housing the IRB. Hub institutions coordinated
participation and approval with these disparate organi-
zations through a combination of collaborative protocol
approvals and implementation activities, ongoing train-
ing activities that often involved a paramedic educator
supported by the study, and ongoing screening of EMS
run logs for evaluation of potential missed enrollments.
Support for a national EMS coordinator for the study,
for local EMS coordinators at each hub, and for leader-
ship effort and payment of training costs as needed
was critically important to this success.
DISCUSSION
The complexities and novelty of the EFIC regulations
are widely thought to have had a chilling effect on the
conduct of emergency research trials, especially multi-
center trials where many IRBs will be involved. The
recent creation of federally funded emergency clinical
trials networks, like the NETT (as well as the Pediatric
Emergency Care Applied Research Network [PECARN]
and the Resuscitation Outcomes Consortium [ROC]),
offers an opportunity to address this concern through
implementation and evaluation of innovative practices.
Building processes for performing EFIC trials within
a clinical trials network has several advantages com-
pared to implementation for a single multicenter trial.
Because the EFIC processes will be repeated and
refined for future trials, the network can justify greater
Table 2
Community Consultation Events and IRB Approval Details by Hub
Hub
















A EGM, B ⁄T, FG 5 130 19 24 5
B EGM, B ⁄T, FG, I 22 11,245 6 11 5
C EGM, B ⁄T, I 23 574 8 22 14
D EGM, B ⁄T, RS 11 212 7 15 9
E EGM, B ⁄T, THM, FG, S, US 20 215 7 17 10
F EGM, FG 8 180 7 14 7
G EGM, I 8 1,635 18 21 3
H EGM, I, THM, B ⁄T, S, US 14 751 12 17 5
I EGM, I, THM, FG, S, US 18 288 8 22 14
J EGM, THM, FG, S, US 16 560 8 17 9
K EGM, US 15 148 3 9 7
L FG, EGM 13 193 8 14 5
M FG, EGM, I 9 260 5 12 6
N RDD, EGM 2 506 20 27 8
O RDD, EGM, US 8 514 9 12 3
P S, FG, US 6 124 5 12 7
Q THM, B ⁄T, EGM, US 30 6,475 3 12 9
Intervals are the number of months: 1) from the RAMPART EFIC meeting until reported IRB approval of a plan for performing
community consultation, 2) from the RAMPART EFIC meeting until final IRB approval to enroll subjects, and 3) from reported
IRB approval of a plan for performing community consultation to final IRB approval to enroll subjects.
B ⁄T = booth or table at event; CC = community consultation; EFIC = exception from informed consent; EGM = existing group
meetings; FG = focus groups; I = face-to-face interviews; IRB = institutional review board; RAMPART = Rapid Anticonvulsant
Medication Prior to Arrival Trial; RDD = random-digit dialing telephone survey; RS = call-in radio show; S = Web or mail surveys;
THM = town hall meetings; US = unscheduled feedback.
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initial investments of time, energy, and resources in
their development. Based on our experience with EFIC
in RAMPART, we refined our database structure and
standardized survey questions for community consulta-
tion for the next EFIC trial being conducted in the
NETT. Furthermore, the network provides an incubator
for empirical investigation in research ethics. These
include an NIH-funded ancillary trial (5R03NS066378-02)
to qualitatively assess RAMPART subject attitudes
about having been enrolled with EFIC. Additional fund-
ing has been obtained to extend this investigation in
the next NETT EFIC trial. These projects, and their con-
tinuity from one trial to the next, directly benefit from
the concerted network approach to EFIC. Similarly,
participating institutions in a network are able to simul-
taneously develop or refine their own expertise in the
review and oversight of EFIC research. Perhaps most
importantly, our model, which emphasizes strong cen-
tral resources and guidance but allows flexibility and
individualization at the local level, provides a dynamic
laboratory for comparing the various experiences of
different sites. For example, a wide array of community
consultation activities was conducted within the NETT
around the same EFIC trial; this ‘‘federated’’ model ulti-
mately may allow identification and recommendation of
best practices.
The cornerstones of the NETT model for network
implementation of EFIC research are 1) development
of central resources, 2) sharing of information and
experiences between sites, and 3) central tracking of
results. Central resources including the NETT HSPC,
study media, and regulatory templates promote effi-
ciency and help ensure a common and accurate mes-
sage. The HSPC and network information technology
are also central resources that enable site-to-site
information and resource sharing. Sharing of infor-
mation and experiences between sites began with the
IRB investigator meeting at the outset of implementa-
tion and continued into the trial. Sites shared solu-
tions to common challenges and exchanged additional
tools they created. Central tracking of EFIC-related
activities allows the NETT to provide consolidated
reporting across the trial to better meet sponsor FDA
and IRB reporting obligations. It also permits compar-
isons among sites and event types and allows the net-
work HSP working group to monitor activities and
advise the trial and network leadership. As seen in
our data, the time to achieve certain EFIC require-
ments varied widely. Investigation of the reasons why
some sites require more time to fulfill the same
requirement for the same study may provide useful
information that can inform NETT investigators
planning future EFIC trials.
Key to the timely and cost-effective implementation
of EFIC in the NETT is adequate and strategically allo-
cated funding. Sites received milestone payments for
completion of essential steps in the EFIC process.
A uniform budget of $50,000 per site was provided to
complete the EFIC-related milestones; this was separate
from the cost of centrally available NETT materials. This
budget was based on the anticipated costs of CC ⁄PD
activities. Actual costs may vary, but a trial of the
magnitude of RAMPART will always require significant
up-front funding to adequately meet the obligations
of EFIC and the desired community engagement and
penetration.
LIMITATIONS
There are several limitations to the description of the
model presented here. While we believe these central
resources reduced the burden of fulfilling the EFIC
requirements, we have no comparative data to verify
our impression. No similar system has published data
from its experiences. We also do not know which cen-
tral resources were most frequently used or were the
most useful. CC ⁄PD activities were self-reported by the
sites and could not be independently monitored for
accuracy. Most of the central resources provided in the
toolbox do not have a metric for their actual utility.
Because the purpose of CC ⁄PD is still not objectively
defined, there is no authoritative way to describe
whether any particular practice is more ‘‘effective’’ than
any other. Available metrics of the performance of
community consultation and public disclosure are
purely observational.
CONCLUSIONS
A coordinated approach to implementation of exception
from informed consent trials within a multicenter clini-
cal trials network promises to improve the quality, effi-
ciency, and accountability of these efforts. The
Neurological Emergencies Treatment Trials provides a
model of network exception from informed consent
implementation in which best practices of community
consultation ⁄public disclosure may be identified and
disseminated. Key elements of successful networkwide
EFIC activities are the provision of central resources
with retained local control and flexibility, sharing of
information and resources between sites, and central
tracking of site activities. Adequate funding and strategic
management of timelines are also important. The Neu-
rological Emergencies Treatment Trials model of EFIC
implementation in a large multicenter clinical trials net-
work was successful in allowing the trial to be per-
formed on time at all hubs. Although there are no
consensus metrics for exception from informed consent
performance, the model appears to be effective and effi-
cient and will continue to be refined in future trials in
the network.
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